Cytokinetics announces start of phase 2 clinical trial of CK-2127107 in patients with COPD
Cytokinetics announced the start of a randomized, double-blind, placebo-controlled, two period crossover clinical trial designed to assess the effect of CK-2127107 on physical function in patients with COPD. CK-107 is a novel fast skeletal muscle troponin activator. June 30, 2016